This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Share
Stay up to date

Home
Topics
Webinars/Videos
Infographics
Articles
Case Studies
Forum
Faculty
Unblocked
Stay up to date

Medications and Therapies Articles

Articles
Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial
Wright RS, Raal FJ, Koenig W, et al.
Journal:
Cardiovasc Res

First published: May 16, 2024 DOI: 10.1093/cvr/cvae109
View
- Share
Articles
Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use
Soroosh GP, Tasdighi E, Adhikari R, et al.
Journal:
Prog Cardiovasc Dis

First published: May 15, 2024 DOI: 10.1016/j.pcad.2024.05.004
View
- Share
Articles
Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN
Nicholls SJ, Nelson AJ, Ditmarsch M, et al.
Journal:
Am Heart J

First published: May 3, 2024 DOI: 10.1016/j.ahj.2024.05.002
View
- Share
Articles
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis
Bonaca MP, Bhatt DL, Simon T, et al.
Journal:
J Am Coll Cardiol

First published: April 30, 2024 DOI: 10.1016/j.jacc.2024.03.377
View
- Share
Articles
Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)
Razavi AC, Richardson LC, Coronado F, et al.
Journal:
Am J Prev Cardiol

First published: April 27, 2024 DOI: 10.1016/j.ajpc.2024.100674
View
- Share
Articles
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT
Burger PM, Bhatt DL, Dorresteijn JAN, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 27, 2024 DOI: 10.1093/ehjcvp/pvae030
View
- Share
Articles
Empagliflozin after Acute Myocardial Infarction
Butler J, Jones WS, Udell JA, et al.
Journal:
N Engl J Med

First published: April 25, 2024 DOI: 10.1056/NEJMoa2314051
View
- Share
Articles
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation
Goodman SG, Steg PG, Szarek M, et al.
Journal:
Eur Heart J Cardiovasc Pharmacother

First published: April 24, 2024 DOI: 10.1093/ehjcvp/pvae025
View
- Share
Articles
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Szarek M, Bhatt DL, Miller M, et al.
Journal:
J Am Coll Cardiol

First published: April 23, 2024 DOI: 10.1016/j.jacc.2024.02.016
View
- Share
Articles
Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial
Sayed A, Brophy JM
Journal:
Int J Cardiol

First published: April 19, 2024 DOI: 10.1016/j.ijcard.2024.132074
View
- Share
Articles
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Articles
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas F, Ray K
Journal:
Expert Opin Pharmacother

First published: April 8, 2024 DOI: 10.1080/14656566.2024.2337253
View
- Share

1 2 3 … 11

How would you rate this content?

Privacy Policy
Terms of use
Stay up to date
Cookie Preferences
This Knowledge Hub is supported by Novartis.

Medications and Therapies Articles

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Articles

Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

Goodman SG, Steg PG, Szarek M, et al.

Articles

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Szarek M, Bhatt DL, Miller M, et al.

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Articles

An update on inclisiran for the treatment of elevated LDL cholesterol

Barkas F, Ray K

Articles

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright RS, Raal FJ, Koenig W, et al.

Share

Articles

Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use

Soroosh GP, Tasdighi E, Adhikari R, et al.

Share

Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

Share

Articles

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis

Bonaca MP, Bhatt DL, Simon T, et al.

Share

Articles

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

Razavi AC, Richardson LC, Coronado F, et al.

Share

Articles

Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT

Burger PM, Bhatt DL, Dorresteijn JAN, et al.

Share

Articles

Empagliflozin after Acute Myocardial Infarction

Butler J, Jones WS, Udell JA, et al.

Share

Articles

Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation

Goodman SG, Steg PG, Szarek M, et al.

Share

Articles

Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl

Szarek M, Bhatt DL, Miller M, et al.

Share

Articles

Effect of bempedoic acid on mortality and cardiovascular events in primary and secondary prevention: A post-hoc analysis of the CLEAR-outcomes trial

Sayed A, Brophy JM

Share

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Share

Articles

An update on inclisiran for the treatment of elevated LDL cholesterol

Barkas F, Ray K

Share